By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ArQule, Inc. 

19 Presidential Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-994-0300 Fax: 781-376-6019



Drug Discovery




Daiichi Sankyo, Inc. 

Company News
ArQule (ARQL) To Present Clinical Data At The 2017 ASCO Annual Meeting 5/18/2017 8:34:54 AM
ArQule (ARQL) To Present Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of European Hematology Association 5/18/2017 8:09:04 AM
ArQule (ARQL) Reports First Quarter 2017 Financial Results 5/3/2017 6:37:55 AM
ArQule (ARQL) Announces Issuance Of U.S. Patent Covering Composition Of Matter Of Proprietary Reversible BTK Inhibitor, ARQ 531 4/26/2017 6:15:16 AM
ArQule (ARQL) To Report First Quarter 2017 Financial Results On May 3, 2017 4/19/2017 6:12:26 AM
ArQule (ARQL) Receives Clearance Of Investigational New Drug Application From The FDA For Proprietary Reversible BTK Inhibitor, ARQ 531 4/11/2017 6:54:16 AM
ArQule (ARQL)'s Lead Liver Cancer Med Bombs Another Phase III, Stock Tanks 3/27/2017 6:12:15 AM
ArQule (ARQL) Reports Fourth Quarter And Full Year 2016 Financial Results 3/7/2017 6:23:16 AM
ArQule (ARQL) To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017 2/24/2017 6:28:55 AM
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017 6:21:54 AM